Open AccessVedolizumab Is Safe and Efficacious for the Treatment of Pediatric-Onset Inflammatory Bowel Disease Patients Who Fail a Primary Biologic Agent
Author(s) -
Sujin Choi,
Eun Sil Kim,
Yiyoung Kwon,
Mi Jin Kim,
Yon Ho Choe,
Byung-Ho Choe,
Ben Kang
Publication year - 2022
Publication title -
journal of korean medical science/journal of korean medical science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.743
H-Index - 66
eISSN - 1598-6357
pISSN - 1011-8934
DOI - 10.3346/jkms.2022.37.e282
Subject(s) - vedolizumab , medicine , hazard ratio , inflammatory bowel disease , ulcerative colitis , retrospective cohort study , confidence interval , proportional hazards model , surgery , disease